NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday recommended brigatinib (Takeda's Alunbrig) for advanced non-small cell lung cancer patients with ALK-rearranged tumors who have previously not received an ALK inhibitor.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.